SEQUENOM INC Form 425 January 28, 2009

## **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

## FORM 8-K

#### **CURRENT REPORT**

## PURSUANT TO SECTION 13 OR 15(d) OF THE

#### **SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): January 28, 2009

# SEQUENOM, INC.

(Exact Name of Registrant as Specified in Charter)

**DELAWARE** (State or Other Jurisdiction

000-29101 (Commission 77-0365889 (I.R.S. Employer

of Incorporation)

File Number)
3595 JOHN HOPKINS COURT

**Identification No.)** 

#### SAN DIEGO, CALIFORNIA 92121

(Address of Principal Executive Offices)

(858) 202-9000

(Registrant s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01. Other Events.

On January 28, 2009, Sequenom, Inc. announced via press release that Sequenom has terminated its exchange offer to acquire all of the outstanding shares of common stock of EXACT Sciences Corporation without accepting for exchange or exchanging any shares of EXACT Sciences common stock. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

#### Exhibit

Number Description

99.1 Press release, dated January 28, 2009.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 28, 2009

SEQUENOM, INC.

By: /s/ Paul Hawran Paul Hawran

Chief Financial Officer

#### EXHIBIT INDEX

Exhibit Number

Description

99.1 Press release, dated January 28, 2009.